The biotech firm has received the finance through the EIB’s new European Growth Finance Facility initiative.

Nuritas, an Ireland-based biotech business, has received €30m ($34m) through a new finance scheme run by the European Union-backed European Investment Bank (EIB).

The firm specialises in artificial intelligence and DNA analysis in the healthcare sector and is the first biotech firm in the country to benefit from the EIB’s new European Growth Finance Facility program.